Premium
Pilot study of pharmacological treatment for frontotemporal dementia: Effect of Yokukansan on behavioral symptoms
Author(s) -
Kimura Takemi,
Hayashida Hideki,
Furukawa Hitomi,
Takamatsu Junichi
Publication year - 2010
Publication title -
psychiatry and clinical neurosciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.609
H-Index - 74
eISSN - 1440-1819
pISSN - 1323-1316
DOI - 10.1111/j.1440-1819.2010.02072.x
Subject(s) - frontotemporal dementia , dementia , medicine , stereotypy , clinical trial , psychology , disease , amphetamine , dopamine
The aim of the present study was to investigate the efficacy of Yokukansan in improving behavioral symptoms of frontotemporal dementia. This study was a prospective, open‐label trial of daily Yokukansan for 4 weeks in 20 frontotemporal dementia patients. Yokukansan treatment was found to significantly improve scores for the Neuropsychiatric Inventory and the Stereotypy Rating Inventory. No adverse effects or significant changes in physical findings and laboratory data occurred except for hypokalemia in two cases. The results indicate that Yokukansan can alleviate the behavioral symptoms of frontotemporal dementia. (The clinical trial registration number is UMIN2704).